Hunan Er Kang Pharmaceutical (300267) — Strategic Asset Allocation Index
Hunan Er Kang Pharmaceutical (300267) has a Strategic Asset Allocation Index of 57.3% as of June 2023. Strategic assets (PP&E of CN¥2.92 Billion plus long-term investments of CN¥-) total CN¥2.92 Billion, measured against net assets of CN¥5.09 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Hunan Er Kang Pharmaceutical Strategic Asset Allocation Index (2008–2022)
This chart shows how Hunan Er Kang Pharmaceutical's Strategic Asset Allocation Index has evolved across 15 annual periods from 2008 to 2022. As of June 2023, the index stands at 57.3%, representing strategic assets of CN¥2.92 Billion against net assets of CN¥5.09 Billion CNY. Explore Hunan Er Kang Pharmaceutical cash flow conversion to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Hunan Er Kang Pharmaceutical (2008–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Hunan Er Kang Pharmaceutical from 2008 to 2022, covering 15 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see market value of Hunan Er Kang Pharmaceutical.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 56.6% | CN¥2.86 Billion | CN¥2.86 Billion | CN¥- | CN¥5.05 Billion | ▲ +3.1 pp |
| 2021 | 53.4% | CN¥2.60 Billion | CN¥2.60 Billion | CN¥- | CN¥4.87 Billion | ▲ +2.4 pp |
| 2020 | 51.1% | CN¥2.96 Billion | CN¥2.96 Billion | CN¥- | CN¥5.79 Billion | ▲ +4.0 pp |
| 2019 | 47.1% | CN¥2.73 Billion | CN¥2.73 Billion | CN¥- | CN¥5.79 Billion | ▲ +1.2 pp |
| 2018 | 45.8% | CN¥2.59 Billion | CN¥2.59 Billion | CN¥- | CN¥5.64 Billion | ▼ -1.8 pp |
| 2017 | 47.7% | CN¥2.58 Billion | CN¥2.58 Billion | CN¥- | CN¥5.41 Billion | ▼ -0.8 pp |
| 2016 | 48.4% | CN¥2.54 Billion | CN¥2.54 Billion | CN¥- | CN¥5.24 Billion | ▲ +13.8 pp |
| 2015 | 34.6% | CN¥1.47 Billion | CN¥1.47 Billion | CN¥- | CN¥4.26 Billion | ▼ -24.8 pp |
| 2014 | 59.4% | CN¥996.61 Million | CN¥996.61 Million | CN¥- | CN¥1.68 Billion | ▲ +21.2 pp |
| 2013 | 38.2% | CN¥509.24 Million | CN¥509.24 Million | CN¥- | CN¥1.33 Billion | ▲ +8.5 pp |
| 2012 | 29.6% | CN¥345.15 Million | CN¥345.15 Million | CN¥- | CN¥1.16 Billion | ▲ +13.9 pp |
| 2011 | 15.7% | CN¥166.94 Million | CN¥166.94 Million | CN¥- | CN¥1.06 Billion | ▼ -54.2 pp |
| 2010 | 69.9% | CN¥123.48 Million | CN¥123.48 Million | CN¥- | CN¥176.62 Million | ▲ +12.7 pp |
| 2009 | 57.2% | CN¥62.89 Million | CN¥62.89 Million | CN¥- | CN¥110.01 Million | ▼ -25.2 pp |
| 2008 | 82.4% | CN¥51.91 Million | CN¥51.91 Million | CN¥- | CN¥63.01 Million | — |